Halozyme Therapeutics Stock Gutted By Revenue Miss, Downgrade

HALO just breached a supportive trendline

Managing Editor
May 11, 2018 at 10:03 AM
facebook twitter linkedin

Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is down 9.3% to trade at $18.12 this morning, after the biotech company reported first-quarter revenue short of analysts' forecasts, as well as a weaker-than-expected full-year guidance. In response, Halozyme  was downgraded to "underweight" from "equal weight" at Barclays.

HALO stock is now on track for its worst day since January 2017. The shares reached a multi-year high of $21.48 on March 20, but promptly pulled back, although the dip was contained by their 160-day moving average. However, the price action today has the security set to close below this trendline for the first time since September.

Additional downgrades and/or price-target cuts could pressure the biotech stock even lower. Of the seven brokerages covering HALO, four rate it a "strong buy," with only a single "sell" on the books. Furthermore, the security's average 12-month price target sits at $20.90, a 13% premium to the stock's current perch.

Elsewhere, short interest has been plummeting on the equity over the past year, down almost 50% from this point last year. But considering the recent technical weakness, these bears could be inclined to target HALO shares once again -- another potential headwinds for the stock.

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1